Uremia and chronic kidney disease: The role of the gut microflora and therapies with pro- and prebiotics

Molecular Nutrition and Food Research

Volumn 57, Issue 5, 2013, Pages 824-832

  Vitetta, Luis ^a   Gobe, Glenda ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Chronic kidney disease; Commensal bacteria; Prebiotics; Probiotics; Uremia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PREBIOTIC AGENT; PROBIOTIC AGENT; TOXIN;

ANIMAL; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; DISEASE MODEL; DRUG EFFECT; GASTROINTESTINAL TRACT; HUMAN; INFLAMMATION; KIDNEY; METABOLISM; MICROBIOLOGY; MICROFLORA; MUCOSA; PATHOLOGY; REVIEW; UREMIA;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; KIDNEY; MICROBIOTA; MUCOUS MEMBRANE; PREBIOTICS; PROBIOTICS; RENAL INSUFFICIENCY, CHRONIC; TOXINS, BIOLOGICAL; UREMIA;

BACTERIA (MICROORGANISMS);

EID: 84876438634     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200714     Document Type: Review

References (69)

1. Dominguez-Bello, M. G., Costello, E. K., Contreras, M., Magris, M. et al., Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. USA 2010, 107, 11971-11975.
2. O'Hara, A. M., Shanahan, F., The gut flora as a forgotten organ. EMBO Rep. 2006, 7(7), 688-693.
3. Mazmanian, S. K., Round, J. L., Kasper, D. L., A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453, 620-625.
4. Wu, J. T., Lin, H. C., Hu, Y. C., Chien, C. T., Neddylation and deneddylation regulate Cul1 and Cul3 protein accumulation. Nat. Cell Biol. 2005, 7, 1014-1020.
5. Tlaskalová-Hogenová, H., Stěpánková, R., Kozáková, H., Hudcovic, T. et al., The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell. Mol. Immunol. 2011, 8, 110-120.
6. Eaton, K. A., Honkala, A., Auchtung, T. A., Britton, R. A., Probiotic Lactobacillus reuteri ameliorates disease due to enterohemorrhagic Escherichia coli in germfree mice. Infect. Immun. 2011, 79, 185-191.
7. Nolan, J. P., The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010, 52, 1829-1835.
8. Hegab, Z., Gibbons, S., Neyses, L., Mamas, M. A., Role of advanced glycation end products in cardiovascular disease. World J. Cardiol. 2012, 4, 90-102.
9. Bone, E., Tamm, A., Hill, M., The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am. J. Clin. Nutr. 1976, 29, 1448-1454.
10. Macfarlane, G. T., Macfarlane, S., Bacteria, colonic fermentation, and gastrointestinal health. J. AOAC Int. 2012, 95, 50-60.
11. Charney, D. I., Walton, D. F., Cheung, A. K., Atherosclerosis in chronic renal failure. Curr. Opin. Nephrol. Hypertens. 1993, 2, 876-882.
12. Schepers, E., Meert, N., Glorieux, G., Goeman, J. et al., p-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol. Dial. Transplant. 2007, 22, 592-596.
13. Motojima, M., Hosokawa, A., Yamato, H., Muraki, T. et al., Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int. 2003, 63, 1671-1680.
14. Dou, L., Bertrand, E., Cerini, C., Faure, V. et al., The uremic solutes p-cresol and indoxylsulfate inhibit endothelial proliferation and wound repair. Kidney Int. 2004, 65, 442-451.
15. Vitetta, L., Briskey, D., Hayes, E., Shing, C. et al., A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics. Inflammopharmacology 2012, 20, 251-266.
16. Hida, M., Aiba, Y., Sawamura, S., Suzuki, N. et al., Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996, 74, 349-355.
17. Levy, A.S., Stevens, L.A., Coresh, J., Conceptual model of CKD: applications and implications. Am. J. Kidney Dis. 2009, 53(S3), S4-S16.
18. Eknoyan, G., Levin, N. W., Eschbach, J. W., Golper, T. A. et al., Baylor College of Medicine; Renal Research Institute; Beth Israel Hospital Center; Minor & James Medical Center; Vanderbilt University; Duke University Medical Center; Covance Health Economics and Outcomes Services; Johns Hopkins University. Continuous quality improvement: DOQI becomes K/DOQI and is updated. National Kidney Foundation's Dialysis Outcomes Quality Initiative. Am. J. Kidney Dis. 2001, 37, 179-194.
19. Twomey, P. J., Reynolds, T. M., The MDRD formula and validation. QJM 2006, 99(11), 804-805.
20. Stenvinkel, P., Ketteler, M., Johnson, R. J., Lindholm, B. et al., IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005, 67, 1216-1233.
21. Nunbhakdi-Craig, V., Machleidt, T., Ogris, E., Bellotto, D. et al., Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex. J. Cell Biol. 2002, 158, 967-978.
22. Parassol, N., Freitas, M., Thoreux, K., Dalmasso, G. et al., Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res. Microbiol. 2005, 156, 256-262.
23. Schneeberger, E. E., Lynch, R. D., The tight junction: a multifunctional complex. Am. J. Physiol. Cell Physiol. 2004, 286, C1213-C1228.
24. Zyrek, A. A., Cichon, C., Helms, S., Enders, G. et al., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 2007, 9, 804-816.
25. Bach, J. F., The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 2002, 47, 911-920.
26. Sironi, M., Clerici, M., The hygiene hypothesis: an evolutionary perspective. Microbes Infect. 2010, 12, 421-427.
27. Strachan, D. P., Hay fever, hygiene, and household size. Br. Med. J. 1989, 299, 1259-1260.
28. Mackay, I. R., Rosen, F. S., Zinkernagel, R. M., Maternal antibodies, childhood infections, and autoimmune diseases. N. Engl. J. Med. 2001, 345, 1331-1335.
29. Limonene, M., Saikku, P., Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Inf. Dis. 2002, 2, 11-17.
30. Libetta, C., Rampino, T., Dal Canton, A., Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am. J. Kidney Dis. 2001, 38, 286-295.
31. Costa, E., Lima, M., Alves, J. M., Rocha, S. et al., Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J. Clin. Immunol. 2008, 28, 268-275.
32. Moser, B., Roth, G., Brunner, M., Lilaj, T. et al., Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: a comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. Biochem. Biophys. Res. Commun. 2003, 308, 581-585.
33. Sester, U., Sester, M., Hauk, M., Kaul, H. et al., T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol. Dial. Transplant. 2000, 15, 1217-1223.
34. Ishizuka, T., Nitta, K., Yokoyama, T., Hayashi, T. et al., Increased serum levels of interleukin-12 may be associated with Th1 differentiation in hemodialysis patients. Nephron 2002, 90, 503-504.
35. Odaka, C. M. T., Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clin. Exp. Immunol. 2000, 121, 515-522.
36. Saubermann, L. J., Nakajima, A., Wada, K., Zhao, S. et al., Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm. Bowel Dis. 2002, 8, 330-339.
37. Hakamada-Taguchi, R., Uehara, Y., Kuribayashi, K., Numabe, A. et al., Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ. Res. 2003, 93, 948-956.
38. Rehermann, B., Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 2009, 119, 1745-1754.
39. Schepers, E., Glorieux, G., Vanholder, R., The gut: the forgotten organ in uremia? Blood Purif. 2010, 29, 130-136.
40. Rook, G. A., Hygiene and other early childhood influences on the subsequent function of the immune system. Dig. Dis. 2011, 29, 144-153.
41. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998, 351, 1225-1232.
42. Wills-Karp, M., Santeliz, J., Karp, C. L., The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat. Rev. Immunol. 2001, 1, 69-75.
43. O'Neill, L. A., How Toll-like receptors signal: what we know and what we don't know. Curr. Opin. Immunol. 2006, 18, 3-9.
44. Pasare, C., Medzhitov, R., Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004, 21, 733-741.
45. Hussaarts, L., van der Vlugt, L. E., Yazdanbakhsh, M., Smits, H. H., Regulatory B-cell induction by helminths: implications for allergic disease. J. Allergy Clin. Immunol. 2011, 128, 733-739.
46. Hoy, W. E., Mathews, J. D., McCredie, D. A., Pugsley, D. J. et al., The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int. 1998, 54, 1296-1304.
47. Stenvinkel, P., Heimbürger, O., Paultre, F., Diczfalusy, U. et al., Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999, 55, 1899-1911.
48. Clavel, T., Haller, D., Molecular interactions between bacteria, the epithelium, and the mucosal immune system in the intestinal tract: implications for chronic inflammation. Curr. Issues Intest. Microbiol. 2007, 8, 25-43.
49. Craig, P. L., Knight, J., Comino, E., Webster, B. et al., Initiation and duration of breastfeeding in an aboriginal community in south western Sydney. J. Hum. Lact. 2011, 27, 250-261.
50. Lawrence, R. M., Pane, C. A., Human breast milk: current concepts of immunology and infectious diseases. Curr. Probl. Pediatr. Adolesc. Health Care 2007, 37, 7-36.
51. Raisler, J., Alexander, C., O'Campo, P., Breastfeeding and infant illness: a dose-response relationship? Am. J. Public Health 1999, 89, 25-30.
52. Glover, M., Waldon, J., Manaena-Biddle, H., Holdaway, M., Cunningham, C., Barriers to best outcomes in breastfeeding for Maori: mothers' perceptions, Whanau perceptions, and services. J. Hum. Lact. 2009, 25, 307-316.
53. Kramer, M. S., Kakuma, R., Optimal duration of exclusive breastfeeding. Cochrane Database Syst. Rev. 2002, 1, CD003517.
54. Krebs, N. F., Jacobson, M. S., Baker, R. D. et al., Prevention of pediatric overweight and obesity. Pediatrics 2003, 112, 424-430.
55. Hoy, W. E., Markers for cardiovascular and renal morbidity: expectations for an intervention program in an Australian Aboriginal community. Clin. Exp. Pharmacol. Physiol. 1996, 23(Suppl 1), S33-S37.
56. Fuller, R., Probiotics in man and animals. J. Appl. Bacteriol. 1989, 66, 365-378.
57. Evenepoel, P., Meijers, B. K., Bammens, B. R., Verbeke, K., Uremic toxins originating from colonic microbial metabolism. Kidney Int. Suppl. 2009, 114, S12-S19.
58. Kotanko, P., Carter, M., Levin, N. W., Intestinal bacterial microflora-a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2006, 21, 2057-2060.
59. Satoh, M., Hayashi, H., Watanabe, M., Ueda, K. et al., Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp. Nephrol. 2003, 95, e111-e118.
60. Ranganathan, N., Patel, B., Ranganathan, P., Marczely, J. et al., Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. Scientific World Journal 2005, 5, 652-660.
61. Simenhoff, M. L., Dunn, S. R., Zollner, G. P., Fitzpatrick, M. E, et al., Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner. Electrolyte Metab. 1996, 22, 92-96.
62. Ranganathan, N., Ranganathan, P., Friedman, E. A., Joseph, A. et al., Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv. Ther. 2010, 27, 634-647.
63. Ranganathan, N., Friedman, E. A., Tam, P., Rao, V. et al., Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr. Med. Res. Opin. 2009, 25, 1919-1930.
64. Meijers, B. K., De Preter, V., Verbeke, K., Vanrenterghem, Y. et al., p-cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol. Dial. Transplant. 2010, 25, 219-224.
65. Nakabayashi, I., Nakamura, M., Kawakami, K., Ohta, T. et al., Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol. Dial. Transplant. 2011, 26, 1094-1098.
66. Hawrelak, J. A., Myers, S. P., The causes of intestinal dysbiosis: a review. Altern. Med. Rev. 2004, 9, 180-197.
67. Coulson, S., Butt, H., Vecchio, P., Gramotnev, H. et al., Green-lipped mussel extract (Perna canaliculus) and glucosamine sulphate in patients with knee osteoarthritis: therapeutic efficacy and effects on gastrointestinal microbiota profiles. Inflammopharmacology 2013, 21, 79-90.
68. O'Dea, K., Trainedes, K., Hopper, J. L., Larkins, R. G., Impaired glucose tolerance, hyperinsulinaemia, and hypertriglyceridaemia in Australian Aborigines from the desert. Diabetes Care 1988, 11, 23-29.
69. Costello, E. K., Stagaman, K., Dethlefsen, L., Bohannan, B. J. et al., The application of ecological theory toward an understanding of the human microbiome. Science 2012, 336, 1255-1262.